NOTV
NASDAQInotiv Inc.
SectorHealth CareIndustryBiotechnology: Commercial Physical & Biological Resarch
News · 26 weeks32+100%
2025-12-282026-06-21
Mix1690d
- Insider8(50%)
- SEC Filings7(44%)
- Other1(6%)
Latest news
25 items- INSIDERChief Financial Officer Taylor Beth A. covered exercise/tax liability with 5,864 shares, decreasing direct ownership by 4% to 139,616 units (SEC Form 4) (for tax liability)4 - Inotiv, Inc. (0000720154) (Issuer)
- INSIDERChief Strategy Officer Sagartz John E covered exercise/tax liability with 6,071 shares, decreasing direct ownership by 0.83% to 729,626 units (SEC Form 4) (tax withholding)4 - Inotiv, Inc. (0000720154) (Issuer)
- INSIDERChief Commercial Officer Hardy Adrian covered exercise/tax liability with 5,371 shares, decreasing direct ownership by 9% to 53,049 units (SEC Form 4) to satisfy withholding tax4 - Inotiv, Inc. (0000720154) (Issuer)
- INSIDERVP-Finance & Corp. Controller Freeman Jeffrey Brennan covered exercise/tax liability with 5,855 shares, decreasing direct ownership by 14% to 36,623 units (SEC Form 4) (tax withholding)4 - Inotiv, Inc. (0000720154) (Issuer)
- INSIDEREVP, GC, Sec'y & CCO Castetter Andrea covered exercise/tax liability with 5,800 shares, decreasing direct ownership by 11% to 49,200 units (SEC Form 4) (for tax liability)4 - Inotiv, Inc. (0000720154) (Issuer)
- INSIDERChief Operating Officer Beattie John Gregory covered exercise/tax liability with 5,769 shares, decreasing direct ownership by 3% to 180,992 units (SEC Form 4) (withholding obligation)4 - Inotiv, Inc. (0000720154) (Issuer)
- SECInotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Inotiv, Inc. (0000720154) (Filer)
- SECInotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Inotiv, Inc. (0000720154) (Filer)
- PRInotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future GrowthReceives commitments for $65 million in new money financing to support ongoing business operations Recapitalization effectuated through a pre-packaged plan of reorganization on an expedited basis Transaction is supported by substantially all of the Company's existing lenders Normal business operations will continue seamlessly with no impact on vendors and suppliers Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it has entered into a Restructuring Support Agreement ("RSA") with
- SECInotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Inotiv, Inc. (0000720154) (Filer)
- INSIDERSEC Form 3 filed by new insider Young John T. Jr.3 - Inotiv, Inc. (0000720154) (Issuer)
- INSIDERSEC Form 3 filed by new insider Davis Eugene I3 - Inotiv, Inc. (0000720154) (Issuer)
- SECInotiv Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Leadership Update, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Inotiv, Inc. (0000720154) (Filer)
- SECSEC Form 10-Q filed by Inotiv Inc.10-Q - Inotiv, Inc. (0000720154) (Filer)
- SECInotiv Inc. filed SEC Form 8-K: Other Events8-K - Inotiv, Inc. (0000720154) (Filer)
- SECInotiv Inc. filed SEC Form 8-K: Other Events8-K - Inotiv, Inc. (0000720154) (Filer)
- SECInotiv Inc. filed SEC Form 8-K: Other Events8-K - Inotiv, Inc. (0000720154) (Filer)
- SECInotiv Inc. filed SEC Form 8-K: Other Events8-K - Inotiv, Inc. (0000720154) (Filer)
- INSIDERChief Financial Officer Taylor Beth A. sold $846 worth of shares (2,888 units at $0.29), decreasing direct ownership by 2% to 145,480 units (SEC Form 4)4 - Inotiv, Inc. (0000720154) (Issuer)
- INSIDERChief Strategy Officer Sagartz John E sold $616 worth of shares (2,119 units at $0.29), decreasing direct ownership by 0.29% to 735,697 units (SEC Form 4)4 - Inotiv, Inc. (0000720154) (Issuer)
- INSIDERPresident and CEO Leasure Robert Jr. sold $4,964 worth of shares (16,810 units at $0.30), decreasing direct ownership by 1% to 1,256,215 units (SEC Form 4)4 - Inotiv, Inc. (0000720154) (Issuer)
- PRInotiv Provides Notice Regarding Cybersecurity IncidentWEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, is providing public notice regarding its cybersecurity incident that it became aware of on August 8, 2025. As previously described in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on August 18, 2025 and its subsequent SEC filings, Inotiv experienced a cybersecurity incident in early August 2025. While Inotiv currently has no indication that perso
- SECSEC Form 10-Q filed by Inotiv Inc.10-Q - Inotiv, Inc. (0000720154) (Filer)
- SECInotiv Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Inotiv, Inc. (0000720154) (Filer)
- PRInotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update– First quarter fiscal 2026 revenue increased 0.8% compared to prior year quarter to $120.9 million – First quarter fiscal 2026 operating loss increased 5.3% compared to prior year quarter to $16.3 million – Conference call scheduled for today at 8:30 am ET WEST LAFAYETTE, Ind., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q1 FY 2026") ended December 31, 2025. Revenue by Segment (in millions of USD) Three Months Ende
NOTV FAQ
6 questionsWhat does Inotiv Inc. do?
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism...Where does NOTV stock trade?
Inotiv Inc. (NOTV) is listed on NASDAQ.What sector and industry is NOTV in?
Inotiv Inc. operates in the Health Care sector, Biotechnology: Commercial Physical & Biological Resarch industry.What are analysts saying about NOTV?
Inotiv Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Hold with a $375.00 price target on 2024-05-14.What companies are similar to NOTV?
Notable peers in the same industry include IQV (IQVIA Holdings Inc.), INCY (Incyte Corp.), PPD (PPD, Inc.), MEDP (Medpace Holdings Inc.), ICLR (ICON plc). Compare NOTV side-by-side with any of them on Quantisnow.How can I track NOTV on Quantisnow?
Quantisnow aggregates Inotiv Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NOTV to receive live email and push alerts on every new disclosure.